Status:
COMPLETED
ADMA Levels in End-Stage Renal Disease
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
Renal Research Institute
Conditions:
Chronic Kidney Disease
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Asymmetric dimethylarginine, ADMA, in plasma, is significantly elevated in patients with renal disease and associated with cardiovascular morbidity and mortality. We found that whole blood (WB) posses...
Eligibility Criteria
Inclusion
- Inclusion
- Group 1:
- are now 18 years of age or older, with end-stage renal disease (ESRD)
- have been on maintenance hemodialysis therapy three times/week for more then 12 months
- Group 2 criteria:
- are now 18 years of age or older
- can be matched to a volunteer in Group 1 for age, gender, race, blood pressure and diabetes history
- have an eGFR greater then 60 ml/min (This is a value based on a laboratory blood test that shows how well your kidneys work.)
- Group 3 criteria:
- are now 18 years of age or older
- have blood pressure less than 130/80 when you are not taking blood pressure medication
- normal kidney function
- Exclusion
- are less then 18 years of age
- are pregnant or breast feeding
- unable or unwilling to provide informed consent
- are currently in another study
- have a hemoglobin (substance in red blood cells that carries oxygen) level that is less than 8 mg/dl
- have an untreated infection that won't go away
- require admission to the hospital
- have a history of hemolytic diseases (e.g. sickle cell disease)
- appear unlikely or unable to participate in the required study procedures
Exclusion
Key Trial Info
Start Date :
July 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 8 2007
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00350974
Start Date
July 1 2006
End Date
March 8 2007
Last Update
June 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109